BAY 2253651 for the treatment of obstructive sleep apnoea: a multicentre, double-blind, randomised controlled trial (SANDMAN)

Thomas Gaisl, Chris D. Turnbull, Gerrit Weimann, Sigrun Unger, Rudolf Finger, Charles Xing, Peter A. Cistulli, Sophie West, Alan K.I. Chiang, Danny J. Eckert, John R. Stradling, Malcolm Kohler

Research output: Contribution to journalLetterpeer-review

1 Downloads (Pure)

Abstract

To the Editor:

For obstructive sleep apnoea (OSA), few mechanical treatment options are available and no pharmacotherapy is approve]. However, safe and efficacious pharmacotherapy would have substantial appeal for many people with OSA.

A promising target is pharmacological treatment increasing upper airway stability by activating the genioglossus muscle. Its activation by the central respiratory control system is importantly modified by mechanoreceptive reflex mechanisms operating locally in the upper airways and modulated by changes in pharyngeal pressure . It has been shown that genioglossus muscle activity and reflex modulation to changes in airway pressure are sleep stage dependent. Many OSA patients have apnoea-free intervals in which genioglossus muscle activity is only 25–40% higher compared with sleep phases with frequent obstructive apnoeas...
Original languageEnglish
Article number2101937
Number of pages5
JournalEuropean Respiratory Journal
Volume58
Issue number5
DOIs
Publication statusPublished - 1 Nov 2021

Keywords

  • obstructive sleep apnoea
  • BAY 2253651
  • Patient outcomes

Fingerprint

Dive into the research topics of 'BAY 2253651 for the treatment of obstructive sleep apnoea: a multicentre, double-blind, randomised controlled trial (SANDMAN)'. Together they form a unique fingerprint.

Cite this